Cancer, Pain
Conditions
Keywords
fentanyl, administration, intranasal, morphine, patient satisfaction, patient preference
Brief summary
Today, patients with cancer pain in need of opioids for moderate to severe pain get long-acting morphine twice a day and morphine tablets taken on demand in addition. This procedure might be based on the assumption that cancer pain is persistent, although the evidence to support whether this assumption applies to all cancer patients is lacking. Some cancer patients might not need a fixed dose of long-acting morphine. Because of rapid pain relief, the new fentanyl drugs open for the possibility to take an opioid on demand when pain occurs. A pilot study where 10 patients with cancer pain were treated with a rapid-acting fentanyl nasal spray taken on demand, showed that this treatment was apparently feasible and safe for these patients. This approach is studied further in NFCP-II. The participants will be treated with rapid-acting fentanyl nasal spray and long-acting morphine in a crossover study. The primary outcome will be patient satisfaction. The study will consist of a test dose of nasal fentanyl, a dose-finding phase and a treatment phase with either nasal fentanyl taken on demand or slow-released morphine taken twice a day. After 10 days of treatment there is a crossover and the opposite drug is used for the same participant. Morphine tablets can be taken on demand in all phases of the study. The participants will meet the investigator at inclusion, at the crossover and at the end of treatment. During the study, a diary is filled in by the participants every morning. Questions about pain and side effects are answered. Satisfaction is measured at the crossover and at end of treatment while preference is measured at the end of treatment.
Interventions
DRUGintranasal fentanyl spray
DRUGslow release morphine
Sponsors
St. Olavs Hospital
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
L'Hospitalet de Llobregat
University Hospital, Bonn
Cantonal Hospital of St. Gallen
Maastricht University Medical Center
Flinders University
Norwegian University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Cancer disease 2. Adult (older than 18 years) 3. Cancer-related pain \> 4 on an 11 point Numerical Rating Scale (NRS) 4. In the need of opioids (step II or III) 5. Able to use nasal drugs. 6. Life expectancy of \> 6 months 7. Karnofsky status \> = 60 8. Women of child bearing potential must use adequate contraception 9. Informed consent given according to applicable requirements before any trial-related activities.
Exclusion criteria
1. Use of opioids for moderate and severe pain 2. History of substance abuse.\* 3. Pathological conditions of the nasal cavity as contraindication to nasal fentanyl 4. Renal- or liver- failure, defined as creatinin \> 150 and alanine-amino transferase (ALAT) \> x 1.5 reference value 5. Sleep apnoea syndrome, severe chronic obstructive lung disease or illnesses leading to severe respiratory depression. 6. Psychiatric disease 7. Neurological disease giving dizziness or sedation 8. Cognitive impairment which makes the patient unable to complete questionnaires or not able to comply with the study procedures. 9. Previous or ongoing facial radiotherapy 10. Recurrent nose bleeding 11. Known hypersensitivity to the active substances or excipients of the study drugs 12. Pregnant or breastfeeding women 13. Treated with monoamine oxidase (MAO) inhibitor within the last 14 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the difference in patient reported satisfaction between the two treatment sessions | 13 days | measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient preference (overall; including pain relief, tolerance to adverse effects and convenience) of treatments after finishing the second part of the clinical study | 26 days | 5 point Likert scale |
| Overall rating of average pain control in the two treatment phases | 26 days | measured by an 11- point numeric rating scale |
| Overall rating of average side effects in the two treatment phase | 26 days | measured by an 11-point numeric rate scales |
Outcome results
None listed